Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

View ORCID ProfileRajith KR Rajoli, Henry Pertinez, View ORCID ProfileUsman Arshad, Helen Box, Lee Tatham, View ORCID ProfilePaul Curley, View ORCID ProfileMegan Neary, Joanne Sharp, View ORCID ProfileNeill J Liptrott, Anthony Valentijn, Christopher David, View ORCID ProfileSteve P Rannard, View ORCID ProfileGhaith Aljayyoussi, View ORCID ProfileShaun H Pennington, Andrew Hill, View ORCID ProfileMarta Boffito, Stephen A Ward, View ORCID ProfileSaye H Khoo, Patrick G Bray, Paul M. O’Neill, W. Dave Hong, View ORCID ProfileGiancarlo Biagini, View ORCID ProfileAndrew Owen
doi: https://doi.org/10.1101/2020.05.01.20087130
Rajith KR Rajoli
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rajith KR Rajoli
Henry Pertinez
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Usman Arshad
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Usman Arshad
Helen Box
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee Tatham
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Curley
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul Curley
Megan Neary
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Megan Neary
Joanne Sharp
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neill J Liptrott
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Neill J Liptrott
Anthony Valentijn
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher David
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve P Rannard
2Department of Chemistry, University of Liverpool, Liverpool, L69 3BX, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steve P Rannard
Ghaith Aljayyoussi
3Centre for Drugs and Diagnostics. Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ghaith Aljayyoussi
Shaun H Pennington
3Centre for Drugs and Diagnostics. Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shaun H Pennington
Andrew Hill
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marta Boffito
4Chelsea and Westminster NHS Foundation Trust and St Stephen’s AIDS Trust 4th Floor, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
5Jefferiss Research Trust Laboratories, Department of Medicine, Imperial College, London, W2 1PG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marta Boffito
Stephen A Ward
3Centre for Drugs and Diagnostics. Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saye H Khoo
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Saye H Khoo
Patrick G Bray
6Pat Bray Electrical, 260D Orrell Road, Orrell, Wigan, WN5 8QZ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul M. O’Neill
2Department of Chemistry, University of Liverpool, Liverpool, L69 3BX, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Dave Hong
2Department of Chemistry, University of Liverpool, Liverpool, L69 3BX, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giancarlo Biagini
3Centre for Drugs and Diagnostics. Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Giancarlo Biagini
Andrew Owen
1Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7 3NY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew Owen
  • For correspondence: aowen@liverpool.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a global pandemic by the World Health Organisation and urgent treatment and prevention strategies are needed. Many clinical trials have been initiated with existing medications, but assessments of the expected plasma and lung exposures at the selected doses have not featured in the prioritisation process. Although no antiviral data is currently available for the major phenolic circulating metabolite of nitazoxanide (known as tizoxanide), the parent ester drug has been shown to exhibit in vitro activity against SARS-CoV-2. Nitazoxanide is an anthelmintic drug and its metabolite tizoxanide has been described to have broad antiviral activity against influenza and other coronaviruses. The present study used physiologically-based pharmacokinetic (PBPK) modelling to inform optimal doses of nitazoxanide capable of maintaining plasma and lung tizoxanide exposures above the reported nitazoxanide 90% effective concentration (EC90) against SARS-CoV-2.

Methods A whole-body PBPK model was constructed for oral administration of nitazoxanide and validated against available tizoxanide pharmacokinetic data for healthy individuals receiving single doses between 500 mg – 4000 mg with and without food. Additional validation against multiple-dose pharmacokinetic data when given with food was conducted. The validated model was then used to predict alternative doses expected to maintain tizoxanide plasma and lung concentrations over the reported nitazoxanide EC90 in >90% of the simulated population. Optimal design software PopDes was used to estimate an optimal sparse sampling strategy for future clinical trials.

Results The PBPK model was validated with AAFE values between 1.01 – 1.58 and a difference less than 2-fold between observed and simulated values for all the reported clinical doses. The model predicted optimal doses of 1200 mg QID, 1600 mg TID, 2900 mg BID in the fasted state and 700 mg QID, 900 mg TID and 1400 mg BID when given with food, to provide tizoxanide plasma and lung concentrations over the reported in vitro EC90 of nitazoxanide against SARS-CoV-2. For BID regimens an optimal sparse sampling strategy of 0.25, 1, 3 and 12h post dose was estimated.

Conclusion The PBPK model predicted that it was possible to achieve plasma and lung tizoxanide concentrations, using proven safe doses of nitazoxanide, that exceed the EC90 for SARS-CoV-2. The PBPK model describing tizoxanide plasma pharmacokinetics after oral administration of nitazoxanide was successfully validated against clinical data. This dose prediction assumes that the tizoxanide metabolite has activity against SARS-CoV-2 similar to that reported for nitazoxanide, as has been reported for other viruses. The model and the reported dosing strategies provide a rational basis for the design (optimising plasma and lung exposures) of future clinical trials of nitazoxanide in the treatment or prevention of SARS-CoV-2 infection.

Competing Interest Statement

AO and SPR are Directors of Tandem Nano Ltd. AO has received research funding from ViiV, Merck, Janssen and consultancy from Gilead, ViiV and Merck not related to the current paper. PON is currently engaged in a collaboration with Romark LLC but this interaction did not influence the prioritisation or conclusions in the current manuscript. No other conflicts are declared by the authors.

Clinical Trial

The paper includes data digitised from previous human clinical trials

Funding Statement

The authors received no funding for the current work. AO acknowledges research funding from EPSRC (EP/R024804/1; EP/S012265/1), NIH (R01AI134091; R24AI118397), European Commission (761104) and Unitaid (project LONGEVITY). GAB acknowledges support from the Medical Research Council (MR/S00467X/1). GA acknowledges funding from the MRC Skills Development Fellowship.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflicts of interest statement AO and SPR are Directors of Tandem Nano Ltd. AO has received research funding from ViiV, Merck, Janssen and consultancy from Gilead, ViiV and Merck not related to the current paper. PON is currently engaged in a collaboration with Romark LLC but this interaction did not influence the prioritisation or conclusions in the current manuscript. No other conflicts are declared by the authors.

  • Funding The authors received no funding for the current work. AO acknowledges research funding from EPSRC (EP/R024804/1; EP/S012265/1), NIH (R01AI134091; R24AI118397), European Commission (761104) and Unitaid (project LONGEVITY). GAB acknowledges support from the Medical Research Council (MR/S00467X/1). GA acknowledges funding from the MRC Skills Development Fellowship.

Data Availability

The data referred to in the manuscript has been cited accordingly as recorded in the references section of the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 06, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis
Rajith KR Rajoli, Henry Pertinez, Usman Arshad, Helen Box, Lee Tatham, Paul Curley, Megan Neary, Joanne Sharp, Neill J Liptrott, Anthony Valentijn, Christopher David, Steve P Rannard, Ghaith Aljayyoussi, Shaun H Pennington, Andrew Hill, Marta Boffito, Stephen A Ward, Saye H Khoo, Patrick G Bray, Paul M. O’Neill, W. Dave Hong, Giancarlo Biagini, Andrew Owen
medRxiv 2020.05.01.20087130; doi: https://doi.org/10.1101/2020.05.01.20087130
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis
Rajith KR Rajoli, Henry Pertinez, Usman Arshad, Helen Box, Lee Tatham, Paul Curley, Megan Neary, Joanne Sharp, Neill J Liptrott, Anthony Valentijn, Christopher David, Steve P Rannard, Ghaith Aljayyoussi, Shaun H Pennington, Andrew Hill, Marta Boffito, Stephen A Ward, Saye H Khoo, Patrick G Bray, Paul M. O’Neill, W. Dave Hong, Giancarlo Biagini, Andrew Owen
medRxiv 2020.05.01.20087130; doi: https://doi.org/10.1101/2020.05.01.20087130

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (240)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1420)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (584)
  • Epidemiology (10297)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2629)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1733)
  • Health Policy (789)
  • Health Systems and Quality Improvement (673)
  • Hematology (266)
  • HIV/AIDS (565)
  • Infectious Diseases (except HIV/AIDS) (12093)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (289)
  • Neurology (2461)
  • Nursing (145)
  • Nutrition (377)
  • Obstetrics and Gynecology (492)
  • Occupational and Environmental Health (568)
  • Oncology (1323)
  • Ophthalmology (401)
  • Orthopedics (146)
  • Otolaryngology (237)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (780)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2397)
  • Public and Global Health (5007)
  • Radiology and Imaging (893)
  • Rehabilitation Medicine and Physical Therapy (528)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (245)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)